

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: * Panel of 60 International HIV-1 Isolates

Catalog Number: 11412

190303 Lot Number:

Release Category: С

Provided: 1 mL cell-free virus of each isolate. Total of 60 isolates, see Tables for descriptions.

Isolates can also be ordered individually by catalog number.

Host Strain: Human PBMCs

Sterility: Negative for mycoplasma, bacteria and fungi

Description: The International Panel of HIV-1 virus isolates consists of ten viruses each from chronically

infected individuals of subtypes A, B, C, D and circulating recombinant forms, CRF01_AE

and CRF02 AG.

Special

The HIV-1 isolates in this panel have been genetically and biologically characterized. The panel contains isolates that use CCR5 as a major coreceptor, CXCR4 or both co-receptors, Characteristics:

and contains both neutralization-sensitive and resistant isolates. This collection provides an important resource for standardization of immunogenicity assessment in HIV-1 vaccine trials (see Table I for genetic and biological characterization of 60 international HIV-1

isolates and see Table II for lot specific analytical data).

Table I. HIV-1 International Panel of HIV-1 Isolates.

Table II. Lot Specific Analytical Data for Each Isolate.

Recommended

Storage:

Keep the reagent in liquid nitrogen.

Contributor: Various; See Table I.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 10/01/2020 Page 1 of 2 References:

Brown, B. K., Darden, J. M., Tovanabutra, S., Oblander, T., Frost, J., Sanders-Buell, E., . . . Polonis, V. R. (2005). Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol, 79(10), 6089-6101. doi:10.1128/JVI.79.10.6089-6101.2005 PUBMED

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from (contributors): (name of clone)." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of Release Category C (Dr. V. Polonis) or D (Dr. N. Michael) Reagents, must contact the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research and Technology Applications (ORTA) at the following email address:

<u>USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil</u>, before reagent(s) can be

released.

Scientist at for-profit institutions or who intend commercial use of Release Category C Reagents (#317 and #510) must contact the NCI Technology Transfer Center at the following email address: <u>lauren.nguyen-antczak@nih.gov</u>, before reagent(s) can be released.

Scientists at for-profit institutions or who intend commercial use of Release Category C (#4648) Reagent, must contact both Dr. Smita Kulkarni (skulkarni@nariindia.org) and Dr. R S Paranjape (rparanjape@nariindia.org) Director, National AIDS Research Institute, before reagent(s) can be released.

Last Updated: October 01, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 10/01/2020 Page 2 of 2